Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis has said it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, after announcing a major delay to the biotech's lead programme pelabresib. The decision – reported in German media outlet WirtschaftsWoche …